| Forty-one recent cases of invasive zygomycosis from a global clinical registry MJGT Rueping, WJ Heinz, AJ Kindo, V Rickerts, C Lass-Floerl, C Beisel, ... Journal of Antimicrobial Chemotherapy 65 (2), 296-302, 2010 | 226 | 2010 |
| Effect of glutamine-enriched total parenteral nutrition in patients with acute pancreatitis J Ockenga, K Borchert, K Rifai, MP Manns, SC Bischoff Clinical nutrition 21 (5), 409-416, 2002 | 162 | 2002 |
| Prognostic factors in 264 adults with invasive Scedosporium spp. and Lomentospora prolificans infection reported in the literature and FungiScope® D Seidel, A Meißner, M Lackner, E Piepenbrock, J Salmanton-García, ... Critical reviews in microbiology 45 (1), 1-21, 2019 | 113 | 2019 |
| Glutamine-enriched total parenteral nutrition in patients with inflammatory bowel disease J Ockenga, K Borchert, E Stüber, H Lochs, MP Manns, SC Bischoff European journal of clinical nutrition 59 (11), 1302-1309, 2005 | 112 | 2005 |
| Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: Final results of the PETRARCA … RD Hofheinz, GM Haag, TJ Ettrich, K Borchert, A Kretzschmar, ... Journal of Clinical Oncology 38 (15_suppl), 4502-4502, 2020 | 89 | 2020 |
| Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal … M Moehler, A Maderer, PC Thuss-Patience, B Brenner, J Meiler, TJ Ettrich, ... Annals of Oncology 31 (2), 228-235, 2020 | 67 | 2020 |
| FLOT versus FLOT/Trastuzumab/Pertuzumab perioperative therapy of human epidermal growth factor receptor 2–positive resectable esophagogastric adenocarcinoma: a randomized phase … RD Hofheinz, K Merx, GM Haag, C Springfeld, T Ettrich, K Borchert, ... Journal of Clinical Oncology 40 (32), 3750-3761, 2022 | 36 | 2022 |
| Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors M Schmitt, X Xu, I Hilgendorf, C Schneider, K Borchert, D Gläser, ... Bone marrow transplantation 48 (7), 922-925, 2013 | 30 | 2013 |
| 1421MO final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone … SE Al-Batran, GM Haag, TJ Ettrich, K Borchert, A Kretzschmar, ... Annals of Oncology 31, S899, 2020 | 24 | 2020 |
| Tenofovir for treatment of hepatitis B virus reactivation in patients with chronic GVHD I Hilgendorf, M Loebermann, K Borchert, C Junghanss, M Freund, ... Bone marrow transplantation 46 (9), 1274-1275, 2011 | 15 | 2011 |
| Posterior reversible encephalopathy syndrome (PRES): an unusual primary manifestation of a diffuse large B-cell lymphoma R Patejdl, K Borchert, H Pagumbke, R Benecke, A Grossmann, F Prall, ... Clinical neurology and neurosurgery 113 (9), 819-821, 2011 | 14 | 2011 |
| Cisplatin/5-FU (CF)+/-panitumumab (P) for patients (pts) with non-resectable, advanced, or metastatic esophageal squamous cell cancer (ESCC): An open-label, randomized AIO/TTD … MH Moehler, PC Thuss-Patience, B Brenner, F Longo, J Meiler, TJ Ettrich, ... Journal of Clinical Oncology 35 (15_suppl), 4011-4011, 2017 | 13 | 2017 |
| Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma: Petrarca—A phase II trial of … R Hofheinz, G zur Hausen, K Borchert, A Kretzschmar, MP Ebert, ... Journal of Clinical Oncology 35 (15_suppl), TPS4133-TPS4133, 2017 | 13 | 2017 |
| Conditioning with treosulfan and fludarabine for patients with refractory or relapsed non‑Hodgkin lymphoma M Schmitt, R Trenschel, HG Sayer, C Schneider, A Glass, I Hilgendorf, ... Molecular and clinical oncology 2 (5), 773-782, 2014 | 13 | 2014 |
| Use of the G-CSF biosimilar Ratiograstim® to mobilize peripheral stem cells in healthy donors for allogeneic stem cell transplantation M Schmitt, D Lena, C Schneider, X Xu, K Borchert, D Gläser, I Hilgendorf, ... Blood 118 (21), 1928, 2011 | 4 | 2011 |
| Cisplatin/5-fluorouracil+/-panitumumab for patients with non-resectable, advanced or metastatic esophageal squamous cell cancer: a randomized phase III AIO/EORTC trial with an … M Moehler, A Maderer, P Thuss-Patience, B Brenner, J Hecker, FL Muñoz, ... Annals of Oncology 29, v103, 2018 | 2 | 2018 |
| trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma: Petrarca—A phase II trial of the German AIO R Hofheinz, G zur Hausen, K Borchert, A Kretzschmar, MP Ebert, ... J Clin Oncol 35, 2017 | 2 | 2017 |
| Overcomming drug-resistance in pancreatic carcinoma H Lampe, D Gläser, C Große-Thie, K Borchert, K Kraft, M Freund, ... Onkologie 36, 68-69, 2013 | 2 | 2013 |
| Application of the G-CSF biosimilar Ratiograstim (R) for the mobilisation of peripheral stem cells in healthy donors M Schmitt, L Diestel, X Xu, K Borchert, D Gläser, I Hilgendorf, ... Onkologie 34, 280-280, 2011 | 2 | 2011 |
| Symptomlast und Krankheitsverlauf bei Patienten mit inkurablen onkologischen Erkrankungen H Maleike, U Düring, C Roll, N Schmidt, K Borchert, C Kahl Zeitschrift für Palliativmedizin 17 (05), P170, 2016 | 1 | 2016 |
